The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Off-Label Use of Predonine for DMD Now Being Reimbursed
The Health Insurance Bureau’s Medical Economics Division issued a director notification to prefectures on February 7 to notify them that from this date the off-label use of Shionogi’s Predonine Tablets 5 mg (prednisolone) for the treatment of Duchenne muscular dystrophy…
To read the full story
Related Article
- Denotas Chewable for Hypocalcemia Associated with Administration of Denosumab Passes PAFSC 1st Committee
February 12, 2013
- Equa Gets Go-Ahead for Additional Concurrent-Use Indications of Insulin and Other Hypoglycemic Agents: PAFSC 1st Committee
February 8, 2013
- PAFSC First Committee Recommends Approval for Japan’s First FD Treatment Acofide
February 8, 2013
REGULATORY
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- Solo Distribution Poses Threats to Stable Supplies, Price Negotiations: Survey
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…